Lia M Halasz1, Hajime Uno2, Melissa Hughes2, Thomas D'Amico3, Elisabeth U Dexter4,5, Stephen B Edge4,5, James A Hayman6, Joyce C Niland7, Gregory A Otterson8, Katherine M W Pisters9, Richard Theriault9, Jane C Weeks2, Rinaa S Punglia10. 1. Department of Radiation Oncology, University of Washington, Seattle, Washington. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. Department of Surgery, Duke Cancer Institute, Durham, North Carolina. 4. Department of Surgery, Roswell Park Cancer Institute, Buffalo, New York. 5. University of Buffalo, Buffalo, New York. 6. University of Michigan, Ann Arbor, Michigan. 7. Information Sciences, City of Hope, Duarte, California. 8. Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio. 9. Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 10. Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract
BACKGROUND: The optimal treatment for patients with brain metastases remains controversial as the use of stereotactic radiosurgery (SRS) alone, replacing whole-brain radiation therapy (WBRT), has increased. This study determined the patterns of care at multiple institutions before 2010 and examined whether or not survival was different between patients treated with SRS and patients treated with WBRT. METHODS: This study examined the overall survival of patients treated with radiation therapy for brain metastases from non-small cell lung cancer (NSCLC; initially diagnosed in 2007-2009) or breast cancer (initially diagnosed in 1997-2009) at 5 centers. Propensity score analyses were performed to adjust for confounding factors such as the number of metastases, the extent of extracranial metastases, and the treatment center. RESULTS: Overall, 27.8% of 400 NSCLC patients and 13.4% of 387 breast cancer patients underwent SRS alone for the treatment of brain metastases. Few patients with more than 3 brain metastases or lesions ≥ 4 cm in size underwent SRS. Patients with fewer than 4 brain metastases less than 4 cm in size (n = 189 for NSCLC and n = 117 for breast cancer) who were treated with SRS had longer survival (adjusted hazard ratio [HR] for NSCLC, 0.58; 95% confidence Interval [CI], 0.38-0.87; P = .01; adjusted HR for breast cancer, 0.54; 95% CI, 0.33-0.91; P = .02) than those treated with WBRT. CONCLUSIONS: Patients treated for fewer than 4 brain metastases from NSCLC or breast cancer with SRS alone had longer survival than those treated with WBRT in this multi-institutional, retrospective study, even after adjustments for the propensity to undergo SRS. Cancer 2016;122:2091-100.
BACKGROUND: The optimal treatment for patients with brain metastases remains controversial as the use of stereotactic radiosurgery (SRS) alone, replacing whole-brain radiation therapy (WBRT), has increased. This study determined the patterns of care at multiple institutions before 2010 and examined whether or not survival was different between patients treated with SRS and patients treated with WBRT. METHODS: This study examined the overall survival of patients treated with radiation therapy for brain metastases from non-small cell lung cancer (NSCLC; initially diagnosed in 2007-2009) or breast cancer (initially diagnosed in 1997-2009) at 5 centers. Propensity score analyses were performed to adjust for confounding factors such as the number of metastases, the extent of extracranial metastases, and the treatment center. RESULTS: Overall, 27.8% of 400 NSCLCpatients and 13.4% of 387 breast cancerpatients underwent SRS alone for the treatment of brain metastases. Few patients with more than 3 brain metastases or lesions ≥ 4 cm in size underwent SRS. Patients with fewer than 4 brain metastases less than 4 cm in size (n = 189 for NSCLC and n = 117 for breast cancer) who were treated with SRS had longer survival (adjusted hazard ratio [HR] for NSCLC, 0.58; 95% confidence Interval [CI], 0.38-0.87; P = .01; adjusted HR for breast cancer, 0.54; 95% CI, 0.33-0.91; P = .02) than those treated with WBRT. CONCLUSIONS:Patients treated for fewer than 4 brain metastases from NSCLC or breast cancer with SRS alone had longer survival than those treated with WBRT in this multi-institutional, retrospective study, even after adjustments for the propensity to undergo SRS. Cancer 2016;122:2091-100.
Authors: B Borgelt; R Gelber; S Kramer; L W Brady; C H Chang; L W Davis; C A Perez; F R Hendrickson Journal: Int J Radiat Oncol Biol Phys Date: 1980-01 Impact factor: 7.038
Authors: Lia M Halasz; Jane C Weeks; Bridget A Neville; Nathan Taback; Rinaa S Punglia Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-09 Impact factor: 7.038
Authors: Paul W Sperduto; Samuel T Chao; Penny K Sneed; Xianghua Luo; John Suh; David Roberge; Amit Bhatt; Ashley W Jensen; Paul D Brown; Helen Shih; John Kirkpatrick; Amanda Schwer; Laurie E Gaspar; John B Fiveash; Veronica Chiang; Jonathan Knisely; Christina Maria Sperduto; Minesh Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2009-11-26 Impact factor: 7.038
Authors: David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran Journal: Lancet Date: 2004-05-22 Impact factor: 79.321
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Mustafa S Ascha; Kaitlyn Funk; Andrew E Sloan; Carol Kruchko; Jill S Barnholtz-Sloan Journal: Clin Exp Metastasis Date: 2019-11-08 Impact factor: 5.150
Authors: Afroz S Mohammad; Jessica I Griffith; Chris E Adkins; Neal Shah; Emily Sechrest; Emma L Dolan; Tori B Terrell-Hall; Bart S Hendriks; Helen Lee; Paul R Lockman Journal: Pharm Res Date: 2018-01-09 Impact factor: 4.200
Authors: Nicolas Meillan; Jean-Emmanuel Bibault; Julien Vautier; Caroline Daveau-Bergerault; Sarah Kreps; Hélène Tournat; Catherine Durdux; Philippe Giraud Journal: Technol Cancer Res Treat Date: 2018-01-01